BIOMAT Database Logo BIOMAT Database Logo

The absorption and elimination of orally administered (14C)hyoscine N-butylbromide (butylscopolamine). 1975

H Vapaatalo, and A Penttilä, and E Kaltiala

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001646 Bile An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum. Biliary Sludge,Sludge, Biliary
D012601 Scopolamine An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. Hyoscine,Scopolamine Hydrobromide,Boro-Scopol,Isopto Hyoscine,Kwells,Scoburen,Scopace,Scopoderm TTS,Scopolamine Cooper,Transderm Scop,Transderm-V,Travacalm HO,Vorigeno,Boro Scopol,Transderm V
D012602 Scopolamine Derivatives Analogs or derivatives of scopolamine. Scopolamines,Derivatives, Scopolamine
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

H Vapaatalo, and A Penttilä, and E Kaltiala
[Inhibition of small intestine motility by orally administered hyoscine-N-butylbromide].
June 1969, Arzneimittel-Forschung,
H Vapaatalo, and A Penttilä, and E Kaltiala
The gastrointestinal absorption and the excretion of H3-butylscopolamine (hyoscine butylbromide) in man.
January 1970, Scandinavian journal of gastroenterology,
H Vapaatalo, and A Penttilä, and E Kaltiala
Enteral absorption of hyoscine N-butylbromide.
November 1967, The Journal of pharmacy and pharmacology,
H Vapaatalo, and A Penttilä, and E Kaltiala
[Testing of orally administered spasmolytics demonstrated by the effect of hyoscine-N-butylbromide on gastric motility].
November 1968, Arzneimittel-Forschung,
H Vapaatalo, and A Penttilä, and E Kaltiala
[Hyoscine N-butylbromide in radiation sickness].
January 1954, L' Arcispedale S. Anna di Ferrara,
H Vapaatalo, and A Penttilä, and E Kaltiala
Hyoscine-N-butylbromide by intravenous infusion.
September 1987, The Medical journal of Australia,
H Vapaatalo, and A Penttilä, and E Kaltiala
The pharmacokinetics of orally administered butylscopolamine in greyhound dogs.
December 2018, Journal of veterinary pharmacology and therapeutics,
H Vapaatalo, and A Penttilä, and E Kaltiala
Haemodynamic effects of hyoscine-N-butylbromide in ponies.
February 1995, Journal of veterinary pharmacology and therapeutics,
H Vapaatalo, and A Penttilä, and E Kaltiala
[The treatment of spastic states with hyoscine-N-butylbromide].
August 1953, Zeitschrift fur arztliche Fortbildung,
H Vapaatalo, and A Penttilä, and E Kaltiala
The Use of Hyoscine N-Butylbromide in Normal Labour.
May 1957, Research newsletter. College of General Practitioners (Great Britain),
Copied contents to your clipboard!